Charles Russell Speechlys advises Apposite Capital on their investment into Mirada Medical
Charles Russell Speechlys has advised healthcare investor Apposite Capital on its £6m investment into medical imaging software business Mirada Medical Limited. Mirada is a leading developer of artificial intelligence (AI) based software which increases the speed and accuracy of cancer treatment planning applications, while delivering a more personalised level of care to patients. Apposite has invested alongside Mirada’s founding investor, Albion Capital, and other private investors.
Sam Gray, Partner at Apposite Capital, commented “We were delighted to work with Richard and team at Charles Russell Speechlys on this deal and appreciated their joined up approach and pragmatic and commercial outlook."
The Charles Russell Speechlys team comprised Rajiv Kakkad and Lydia Zakrzewski (Private Equity), Kirsti Laird (Employment), Caroline Young and Jaclyn Wilkins (Commercial and IP) and Helen Coward and Elliot Michaelson (Tax).
News & Insights
COVID-19 update: Companies House filings
New regulations were launched on 26 June that will temporarily extend the various filing deadlines for companies.
Government provides welcome clarity for EMI option holders who have been furloughed
The proposed amendments will provide some clarity and address concerns regarding the consequences of furloughing EMI option holders.
Charles Russell Speechlys advises Transense Technologies Plc on iTrack technology transaction with Bridgestone Corporation
Transense Technologies Plc, the provider of sensor systems for the industrial, mining and transportation markets.
Charles Russell Speechlys advises Kreos and SVB on $70m private placement for AIM listed Mereo BioPharma Group plc
Mereo BioPharma is a clinical stage UK-based biopharmaceutical company listed on the AIM market of the LSE.